The BD SurePath™ liquid-based Pap test provides advantages over conventional Pap smears and other liquid-based cytology (LBC) tests, resulting in greater disease detection.
true
{"AlternateComparison":false,"RelatedProducts":false,"Specification":true,"FeatureBenefit":false}
BD SurePath™
Clinical diagnostic reagents
BD SurePath™ liquid-based Pap test
![Icon to close thank you modal]()
BD PrepStain™ Consumable Kit, 480 Tests
Support
Singapore (Greater Asia Head Office)
+65 6664 2700
bd_sea@bd.com
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
Address
2 International Business Park Road, #08-08 The Strategy, Singapore 609930
- Overview
- Specifications
- eIFUs and Resources
- FAQ
- Product Notifications
true
FEATURE AND BENEFIT CARDS NOT AVAILABLE
FEATURE AND BENEFIT CARDS NOT AVAILABLE
GTIN - Each
00382904914547
1
Quantity - Each
1
Shelf Life (Days)
730
GTIN
| GTIN - Each | 00382904914547 | 1 |
Packaging
| Quantity - Each | 1 |
Storage and Handling
| Shelf Life (Days) | 730 |
false
Things to Consider
If you are a patient or end user, you can contact us yourself, or you may have your caregiver or your physician do that for you. To help us process your
information quickly and effectively, please contact our customer complaints
team.
To better facilitate our investigation, please include the following information in your reporting:
- Product Name and/or Catalog Number
- Lot Number or Serial Number
- Any injuries and/or Harm?
- What is the issue you experienced?
- Is the actual sample or sample representative available? (If possible, please send affected sample)
- Contact name and phone number
- BD PrepStain™ slide processor: direct-to-vial study population [product insert]. Franklin Lakes, NJ: Becton, Dickinson and Company; 2016.
- Fremont-Smith M, Marino J, Griffin B, Spencer L, Bolick D. Comparison of the Surepath liquid-based Papanicolaou smear with the conventional Papanicolaou smear in a multisite direct-to-vial study. Cancer. 102:269-279.
- Nygård JF, Sauer T, Nygård M, Skare GB, Thoresen S Ø. CIN 2/3 and cervical cancer in an organised screening programme after an unsatisfactory or a normal Pap smear: a seven-year prospective study of the Norwegian population-based screening programme. J Med Screen. 2004;11(2):70-76.
- Nance KV. Evolution of Pap testing at a community hospital: a ten year experience. Diagn Cytopathol. 2007:35(3):148-153.
true
true